investorscraft@gmail.com

Stock Analysis & ValuationNextStage SCA (NEXTS.PA)

Professional Stock Screener
Previous Close
105.00
Sector Valuation Confidence Level
High
Valuation methodValue, Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Method344.63228
Graham Formulan/a

Strategic Investment Analysis

Company Overview

NextStage SCA is a France-based private equity firm specializing in long-term investments in medium-sized, mid-cap, mature, and growth capital companies across Europe. Operating as a subsidiary of NextStage AM, the firm targets a diversified portfolio, with 75% allocated to unlisted mid-cap companies and the remainder to listed mid-cap firms on Euronext or Alternext. NextStage invests between €8 million and €40 million in companies with revenues ranging from €10 million to €500 million and enterprise values between €25 million and €200 million. The firm avoids biotech but otherwise invests across all sectors, focusing on value creation through strategic capital deployment. With a strong presence in the European private equity landscape, NextStage leverages its expertise in mid-market investments to drive growth and operational improvements in its portfolio companies. Its disciplined investment approach and sector-agnostic strategy position it as a key player in the European financial services and asset management industry.

Investment Summary

NextStage SCA presents a niche investment opportunity in the European mid-market private equity space, characterized by its disciplined capital allocation and focus on unlisted and listed mid-cap companies. The firm's FY 2021 financials show a net income of €25.4 million, with diluted EPS of €0.24, though operating cash flow was negative at €-2.6 million. With a low beta of 0.21, NextStage may appeal to investors seeking lower volatility exposure to private equity. However, the absence of dividends and negative operating cash flow could deter income-focused investors. The firm's €39.98 million cash position provides liquidity, but its €17.1 million debt load warrants monitoring. Given its specialized focus, NextStage is best suited for investors bullish on European mid-market growth and comfortable with illiquidity risks inherent in private equity.

Competitive Analysis

NextStage SCA competes in the crowded European mid-market private equity sector, differentiating itself through a sector-agnostic approach (excluding biotech) and a balanced mix of listed and unlisted investments. Its competitive advantage lies in its deep regional expertise and ability to identify undervalued mid-cap companies with growth potential. The firm's investment range (€8-40 million) positions it between smaller venture capital players and larger buyout funds, allowing it to capitalize on a market segment often overlooked by mega-funds. However, its lack of sector specialization may limit value-add capabilities compared to industry-focused peers. NextStage's subsidiary relationship with NextStage AM provides operational synergies but may also create conflicts of interest. The firm's French base gives it local market advantages in Francophone Europe but may limit penetration in Northern or Eastern European markets where local players dominate. Its negative operating cash flow in 2021 suggests portfolio companies may require further capital injections, potentially straining resources.

Major Competitors

  • Eurazeo SE (EPA.PA): Eurazeo is a larger French private equity firm with global reach and €31.5 billion in assets under management. It competes directly with NextStage in European mid-market deals but has greater scale and sector-specific platforms. Eurazeo's diversified structure (including listed holdings) provides liquidity advantages but may lack NextStage's focus on pure mid-market value creation.
  • IPSOS SA (IPS.PA): Ipsos is primarily a market research firm but overlaps with NextStage in data-driven investment strategies. While not a direct private equity competitor, its analytics capabilities could threaten NextStage's deal sourcing edge in consumer-facing sectors. Ipsos' strong cash flow generation contrasts with NextStage's negative operating cash flow.
  • Atos SE (ATO.PA): Atos operates in IT services but competes for mid-market tech investments where NextStage may deploy capital. Atos' struggling performance (€3 billion net loss in 2023) demonstrates risks in sectors NextStage avoids, validating its diversified approach. However, Atos' scale in digital transformation could pressure NextStage's tech portfolio companies.
  • Argan SA (ARG.PA): Argan is a specialized real estate investment firm that competes with NextStage for capital allocation in property-related mid-market deals. Its focus on logistics real estate (€4.1 billion portfolio) gives it sector depth NextStage lacks, but Argan's narrower mandate limits its investment flexibility across industries.
HomeMenuAccount